Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice
Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice
复制标题
DOI:
10.1016/s0301-472x(99)00087-9
复制
发表时间:
1999-10-01
影响因子:
2.6
通讯作者:
Car, BD
中科院分区:
文献类型:
--
作者:
Lorenz, M;Slaughter, HS;Car, BD
Cyclooxygenase (COX) plays a key regulatory role in prostaglandin synthesis. COX-2 is inducible and is the major isoform of inflammatory cells. COX-2-deficient mice were shown to have normal basal hematopoiesis and hematology. We hypothesized that COX-2 induction plays a role in the recovery phase of 5-fluorouracil (5-FU) induced bone marrow injury, because significant macrophage-driven phagocytic removal of necrotic debris and stromal cell reorganization of repopulating marrow occur after 5-FU induction of bone marrow necrosis. Hematologic recovery was markedly delayed with moderately severe leukopenia, thrombocytopenia and reticulocytopenia compared to heterozygotes on day 8 or 12 in Cox-2(-/-) mice. Mild anemia mas present in 5-FU-treated Cox-2(-/-) and Cox-2(+/-) mice on days 8 and 12, which was more severe in Cox-2(-/-) mice, Cox-2(-/-) mice had markedly deer-eased bone marrow cell counts per femur and reduced numbers of erythroid and myeloid colony-forming cells compared to heterozygote mice on days 8 and 12 post 5-FU, Histologic examination of 5-FU-treated Cox-2(-/-) mice revealed a failure to repopulate the intact marrow stroma with hematopoietic cells. Accelerated erythropoiesis following phenylhydrazine-induced hemolytic anemia, however, was comparable between Cox-2(-/-) and Cox(+/-) mice, as were induced levels of renal erythropoietin mRNA. COX-2 induction is likely a central event in the accelerated hematopoiesis following myelotoxic injury, because recovery from 5-FU-induced myeloablation is markedly impaired in Cox-2(-/-) mice but is normal after phenylhydrazine induction of anemia, (C) 1999 International Society for Experimental Hematology. Published by Elsevier Science Inc.